Tissue-repair, gut & immune-signalling peptides
Abaloparatide
Also known as Tymlos · Eladynos · PTHrP(1-34) analogue
A synthetic analogue of parathyroid hormone-related protein (PTHrP 1–34) that selectively activates the PTH1 receptor to build bone.
In 60 seconds
Approved for postmenopausal osteoporosis (prescription-only); the ACTIVE phase 3 trial measured vertebral fractures. Reviews and a 2024 meta-analysis report palpitations, dizziness and hypercalcaemia among adverse events.
- The ACTIVE phase 3 trial measured new vertebral fractures with abaloparatide versus placebo.
- A meta-analysis of abaloparatide’s efficacy and safety in postmenopausal osteoporosis.
- Maps preclinical and clinical knowledge of abaloparatide.
Mechanism
Abaloparatide shares its first 20 amino acids with PTHrP and favours a receptor conformation linked to transient signalling, which is proposed to give a bone-forming effect with less stimulation of resorption than teriparatide.
Research status
Approved for postmenopausal osteoporosis (prescription-only); the ACTIVE phase 3 trial measured vertebral fractures.
Key studies
The ACTIVE phase 3 trial measured new vertebral fractures with abaloparatide versus placebo.
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial — JAMA, 2016 · PMID 27533157
A meta-analysis of abaloparatide’s efficacy and safety in postmenopausal osteoporosis.
The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis — Clin Ther, 2024 · PMID 38307725
Maps preclinical and clinical knowledge of abaloparatide.
Abaloparatide: A review of preclinical and clinical studies — Eur J Pharmacol, 2021 · PMID 34364879
Compares the three bone-anabolic agents in postmenopausal osteoporosis.
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis — J Bone Miner Metab, 2025 · PMID 39009890
Safety signals in the literature
Reviews and a 2024 meta-analysis report palpitations, dizziness and hypercalcaemia among adverse events.
Legal status (South Africa)
Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Abaloparatide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Abaloparatide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Abaloparatide?
A synthetic analogue of parathyroid hormone-related protein (PTHrP 1–34) that selectively activates the PTH1 receptor to build bone. Abaloparatide shares its first 20 amino acids with PTHrP and favours a receptor conformation linked to transient signalling, which is proposed to give a bone-forming effect with less stimulation of resorption than teriparatide.
What is the research status of Abaloparatide?
Approved for postmenopausal osteoporosis (prescription-only); the ACTIVE phase 3 trial measured vertebral fractures.
What safety signals are reported for Abaloparatide?
Reviews and a 2024 meta-analysis report palpitations, dizziness and hypercalcaemia among adverse events.
Does Living Water Labs stock Abaloparatide?
Not at present. Abaloparatide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
More in Repair & immune
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
